Patented Medicine Prices Review Board

Topic 1: PMPRB Panel   On Tuesday, June 13, 2017, the Canadian Association for Healthcare Reimbursement (CAHR) held its Market Access 201 conference in Toronto. The theme for this conference was Parallel or Intersecting Paths, the Future of Public and Private Reimbursement in Canada which consisted of five engaging panels focusing on key topics of interest to the Canadian pharmaceutical stakeholders. Over the coming weeks, MORSE will be releasing summaries…

Consultations Commence for Major Changes to Canadian Pharmaceutical Policy   On May 16, 2017, the Federal Minister of Health, the Hon. Jane Philpott presented several major announcements, which are likely to have significant impacts on both national and provincial/territorial pharmaceutical policy.  The announcements covered an array of developments including: changes to the regulations that govern how the Patented Medicine Prices Review Board (PMPRB) operates; enhancing the capacity of the pan-Canadian…

The Patented Medicine Prices Review Board Provides an Update on its Activities   The Patented Medicine Prices Review Board (PMPRB) released its first Newsletter of 2017.  This bulletin provides updates related to: Guidelines Modernization Upcoming Reports: NPDUIS Update New Policy:  Complaint process for patented generic-drug price reviews PMPRB Governance/Administration Status of Ongoing Hearings Regulatory Details: CPI Adjustment Factors for 2017 Please see summary below for further information: Guidelines Modernization Submissions…